Physician
Hematology
Dr. Ronald G. Steis, MD
|
|
Give Review
Ronald G. Steis is an expert in the field of Hematology. He went to medical school at University of Pittsburgh School of Medicine. He has 1 awards "Top MD". Doctor Ronald G. Steis, MD has written publications. He has 76 publications published with PubMed. The lastest paper is: 'A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Netw...
- Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung Cancer: a multicenter phase 2 study.
- InDuction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung can...
- Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multi...
- Phase i/ii trial of 5-Fluorouracil, leucovorin, Zidovudine and dipyridamole for patients with metastatic colorectal-Cancer, renal-cell carcinoma and malignant-melanoma.
- Bone marrow transplantation: Cancer therapy comes of age.
- Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl Cancer research network.
- Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin's Lymphoma.
- Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
- A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
- A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell Carcinoma.
- Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
- Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced Cancer.
- Immunomodulatory effects of interferon-gamma in patients with metastatic Malignant melanoma.
- Dose-related immunologic effects of levamisole in patients with Cancer.
- Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.
- T-cell receptor gene rearrangement in T-cell large granular leukocyte Leukemia: preferential V alpha but diverse J alpha usage in one of five patients.
- Clinical relevance of recombinant interferon-alpha 2a antibodies in patients with hairy cell Leukemia.
- Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results.
- Pharyngeal obstruction by Kaposi's sarcoma in a homosexual male with acquired Immune deficiency syndrome.
- Kaposi's sarcoma of the head and neck in the acquired Immune deficiency syndrome.
- Partial Immune reconstitution in a patient with the acquired immunodeficiency syndrome.
- Role of interferon in AIDS.
- Ophthalmic involvement in acquired immunodeficiency syndrome.
- Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome.
- Acquired immune deficiency syndrome (AIDS) and Kaposi's sarcoma: clinical relationship between immunodeficiency disease and Cancer.
- Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency syndrome.
- Correlation between immunologic function and clinical subpopulations of patients with the acquired Immune deficiency syndrome.
- Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired Immune deficiency syndrome. Clinical response and prognostic parameters.
- Response to 2'-deoxycoformycin after failure of interferon-alpha in nonsplenectomized patients with hairy cell Leukemia.
- Resistance to recombinant interferon alfa-2a in hairy-cell Leukemia associated with neutralizing anti-interferon antibodies.
- Treatment of peripheral neuroepithelioma in children and young adults.
- Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance.
- Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell Leukemia.
- The determination of an immunologically active dose of interferon-gamma in patients with melanoma.
- Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell Lymphoma.
- Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T Cells and natural killer Cells in patients with the acquired immunodeficiency syndrome.
- Interferon-induced 2'-5' oligoadenylate synthetase during interferon-alpha therapy in homosexual men with Kaposi's sarcoma: marked deficiency in biochemical response t...
- Lymph node pathology of HTLV and HTLV-associated Neoplasms.
- Retrovirus-like particles in salivary Glands, prostate and testes of AIDS patients.
- Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell Leukemia patient resistant to interferon-alpha.
- Diffuse osteosclerosis in hairy cell Leukemia.
- Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients.
- Adrenal insufficiency and interleukin-2 therapy.
- Hypothyroidism after interleukin-2 therapy.
- Deoxycoformycin-induced immunosuppression in patients with hairy cell Leukemia.
- Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic Malignant melanoma.
- Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal Cancer: immunologic considerations.
- Comparison of monoclonal antibodies for the detection of occult Breast carcinoma metastases in bone marrow.
- Clinical, biologic, and therapeutic aspects of malignancies associated with the acquired immunodeficiency syndrome: Part I and Part II.
- Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired Immune deficiency syndrome.
- An evaluation of the toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic coloRectal carcinoma.
- Erythrocytosis in hairy Cell leukaemia following therapy with interferon alpha.
- Exacerbation of symptoms of autoimmune Disease in patients receiving alpha-interferon therapy.
- Treatment of hairy cell Leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.
- Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's Lymphoma.
- Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
- Immunomodulatory properties and toxicity of interleukin 2 in patients with Cancer.
- Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
- Intraperitoneal lymphokine-activated killer-Cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
- Myocarditis or Acute myocardial infarction associated with interleukin-2 therapy for cancer.
- Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial.
- Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection.
- The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.
- Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.
- Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell Leukemia.
- Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
- Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic coloRectal carcinoma.
- Kinetics of recovery of CD4+ T Cells in peripheral blood of deoxycoformycin-treated patients.
- Pilot study of interleukin-2 and lymphokine-activated killer Cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patien...
- The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
- Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with Cancer: clinical and immunol...
- Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.
- Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.
- Bovine Adrenal cortical protein kinases: isolation of the type II catalytic subunit.
Schools
University of Pittsburgh School of Medicine
University Of Pittsburgh
Nci
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Top MD
Education
-
National Institutes of Health Clinical Center -
University of Pittsburgh Medical Center -
University of Pittsburgh School of Medicine
Hospital
-
North Fulton Regional Hospital -
Northside Hospital -
Emory Saint Joseph's Hospital of Atlanta
Drug Facts
| NPI NUMBER | 1205875218 | |
| NPPES Provider LastName | STEIS | |
| NPPES Provider FirstName | RONALD | |
| NPPES Provider ZIPCode | 300053707 | |
| NPPES Provider State | GA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1908.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 159.0 | |
| Percent Opioid Claims | 8.33 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205875218 |
| Last Name Of The Provider | STEIS |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
|
Dr. Silpa C. Reddy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karthi Subbannan, MD
This Doctor is OpenDoctor Recommended.
|